NEW YORK – Biocept said on Tuesday that it has been awarded the CE-IVD mark for its Target Selector EGFR mutation detection assay, allowing the company to commercialize the kits throughout the European Union and other CE mark geographies.
Biocept's Target Selector technology is designed to support individual mutation assays targeting key oncogene mutations. It uses a patented "switch-blocker" method to enrich a specimen for mutations of interest, increasing sensitivity and specificity.